BRD9 and cancer: To further examine the translational relevance of BRD9 as a candidate therapeutic target, we used freshly isolated primary cancer patient samples and treated them with I-BRD9 or in combination with gemcitabine for 72 hours followed by single-cell RNA-sequencing (Figure 4A) for ~12,000 cells.